SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-23-004277
Filing Date
2023-03-23
Accepted
2023-03-23 17:05:03
Documents
13
Period of Report
2023-03-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-8k_20230321.htm   iXBRL 8-K 35642
2 EX-10.1 achv-ex101_6.htm EX-10.1 28600
  Complete submission text file 0001564590-23-004277.txt   201169

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA achv-20230321.xsd EX-101.SCH 5617
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20230321_lab.xml EX-101.LAB 20039
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20230321_pre.xml EX-101.PRE 11943
7 EXTRACTED XBRL INSTANCE DOCUMENT achv-8k_20230321_htm.xml XML 3674
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 23756988
SIC: 2835 In Vitro & In Vivo Diagnostic Substances